Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176676 | 0.97 | NLRP3 (0.42) | NOS2NOS3NOS1KDM4ENLRP3 | |
| SCHEMBL176478 | 0.93 | CNR2 (0.38) | NOS2NOS3NOS1KDM4EITGA4 | |
| SCHEMBL4209660 | 0.91 | OPRM1 (0.40) | ITGA4ITGB7 | |
| SCHEMBL14089768 | 0.89 | CTSL (0.36) | ITGA4ITGB7NLRP3 | |
| SCHEMBL176718 | 0.89 | NLRP3 (0.41) | ITGA4ITGB7NLRP3 | |
| SCHEMBL4210979 | 0.88 | MME (0.39) | ITGA4ITGB7 | |
| SCHEMBL14089550 | 0.85 | NOS2 (0.38) | NOS2NOS3NOS1KDM4ENLRP3 | |
| SCHEMBL4909261 | 0.84 | CNR2 (0.41) | ITGA4ITGB7 | |
| SCHEMBL177042 | 0.83 | CNR2 (0.43) | NLRP3 | |
| SCHEMBL176542 | 0.83 | CNR1 (0.46) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | claimed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | claimed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | claimed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | claimed |
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2139328-A2 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-01-06 | — | — | EP | disclosed |
| EP-1937259-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | disclosed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | disclosed |
| WO-2007038036-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038036-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | NOS2 3524/4885NOS3 3506/4885NOS1 3547/4885 |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | CNR2, CNR1, FAAH | NOS2 3524/4885NOS3 3506/4885NOS1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.